# with relapsed or refractory multiple myeloma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/with-relapsed-or-refractory-multiple-myeloma

> No upcoming FDA catalysts in with relapsed or refractory multiple myeloma; 2 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 28, 2022 | [CARVYKTI (ciltacabtagene autoleucel) FDA approval](https://sec-api.dev/pdufa/ciltacabtagene-autoleucel) | LEGN | with relapsed or refractory multiple myeloma | completed, approved | "On February 28, 2022, the FDA approved our product CARVYKTI (cilta-cel) for the treatment of adults with RRMM who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1801198/000180119825000012/legn-20241231.htm)) |
| Mar 2026 | [TECVAYLI (teclistamab) FDA approval](https://sec-api.dev/pdufa/teclistamab) | HALO | with relapsed or refractory multiple myeloma | completed, approved | "•In March 2026, Janssen announced the FDA approved TECVAYLI® (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000067/ex991q120268-k.htm)) |

## Drugs

- [CARVYKTI (ciltacabtagene autoleucel)](https://sec-api.dev/pdufa/ciltacabtagene-autoleucel) (JNJ)
- [TECVAYLI (teclistamab)](https://sec-api.dev/pdufa/teclistamab) (JNJ)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/with-relapsed-or-refractory-multiple-myeloma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "with relapsed or refractory multiple myeloma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/with-relapsed-or-refractory-multiple-myeloma

```bibtex
@misc{secapidev_indications_with_relapsed_or_refractory_multiple_myeloma_20261116,
  title        = {with relapsed or refractory multiple myeloma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/with-relapsed-or-refractory-multiple-myeloma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_with_relapsed_or_refractory_multiple_myeloma_20261116","title":"with relapsed or refractory multiple myeloma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/with-relapsed-or-refractory-multiple-myeloma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
